Refine
Departments, institutes and facilities
Document Type
- Article (124)
- Part of a Book (3)
- Preprint (2)
Year of publication
Keywords
- Organic aciduria (5)
- Inborn error of metabolism (4)
- Ketolysis (4)
- organic aciduria (4)
- Ketogenesis (3)
- Ketone body (3)
- Metabolic acidosis (3)
- metabolic acidosis (3)
- 3-hydroxyisobutyrate dehydrogenase (2)
- 3-hydroxyisobutyric aciduria (2)
- ACAT1 (2)
- Aminoacylase (2)
- Canavan disease (2)
- Enzyme activity (2)
- Fatty acid metabolism (2)
- GLYCTK (2)
- Glycine conjugation (2)
- HIBADH (2)
- HIBADH deficiency (2)
- HMGCL (2)
- Hyperammonemia (2)
- Isovaleric acidemia (2)
- Ketoacidosis (2)
- Ketone body utilization (2)
- Metabolic decompensation (2)
- Metabolicdecompensation (2)
- Movement disorder (2)
- d-Glycerate kinase deficiency (2)
- d-Glyceric aciduria (2)
- inborn error of metabolism (2)
- isoleucine (2)
- ketogenesis (2)
- ketolysis (2)
- ketone body (2)
- leucine (2)
- metabolic decompensation (2)
- 3-hydroxy-n-butyric acid (1)
- 3-hydroxyisobutyrate dehydrogenase deficiency (1)
- 3-hydroxyisobutyric acid dehydrogenase deficiency (1)
- 5-Oxoprolinase (1)
- 5-oxoprolinuria (1)
- ACacylcarnitines (1)
- AMAtypical myopathy (1)
- AMT (1)
- ASPA (1)
- Acylpeptide hydrolase (1)
- Aminoacylase 1 (1)
- Aspartoacylase (1)
- Autism (1)
- Beta-ketothiolase (1)
- Beta-ketothiolase deficiency (1)
- Biotin (1)
- Carbapenem (1)
- DBSdried blot spots (1)
- Dehydrogenase (1)
- Dystonia (1)
- Enantioselective gas chromatography (1)
- Enzyme activity assays (1)
- Epilepsy (1)
- Fructose (1)
- GC–MSgas chromatography–mass spectrometry (1)
- Glutathione synthetase (1)
- Glycerate (1)
- Glyceric aciduria (1)
- Glycine N-Acyltransferase (GLYAT) (1)
- Glycine N-acyltransferase (1)
- Glycogen storage disease type (1)
- HSD10 (1)
- Health care policy (1)
- Hypoglycemia (1)
- Inborn errors of metabolism (1)
- Inherited metabolic disorders (1)
- Intellectual disability (1)
- Isoleucine (1)
- Isoleucine degradation (1)
- Ketoasidoz (1)
- Ketogenic diet (1)
- Ketone body synthesis (1)
- Kozak-sequence (1)
- Leucine (1)
- Leucine degradation (1)
- MADDMultiple acyl-CoA dehydrogenase deficiency (1)
- MCT (1)
- MOCS1 (1)
- MRPP (1)
- Magnetic resonance imaging (MRI) (1)
- Metabolic stroke (-like event) (1)
- Methylmalonic acidemia (1)
- Methylmalonic aciduria (1)
- Methylmalonyl-CoAmutase (1)
- Methyltransferase (1)
- Mitochondrial tRNA (1)
- Moco deficiency (1)
- Molybdenum cofactor (1)
- Monocarboxylate transporter 1 (1)
- N-acetylaspartic acid (1)
- N-acylated amino acids (1)
- N-isovalerylglycine (1)
- Neugeborenenscreening (1)
- Neurometabolic disease (1)
- Next generation sequencing (1)
- Nonketotic hyperglycinemia (1)
- OA, organic acids (1)
- OXCT1 (1)
- Organic acids (1)
- Organische Säuren (1)
- Pharmacogenetics (1)
- Phase II reaction (1)
- Polymorphism (1)
- Propionic acidemia (1)
- Propionic aciduria (1)
- Propionyl-CoA carboxylase (1)
- Pyroglutamic aciduria (1)
- S-sulfocysteine (1)
- SARS-COV-2 virus (1)
- SLC (1)
- Seizures (1)
- Selektives Screening (1)
- Serine (1)
- Splicing (1)
- Sulfite oxidase (1)
- Survey (1)
- Tandem-Massenspektrometrie (1)
- Telemedicine (1)
- Urea cycle defect (1)
- Urinary organic acids (1)
- Urine organic acid analysis (1)
- Urothione (1)
- Valproic acid (1)
- Vitamin B12/adenosylcobalamin (1)
- acetoacetic acid (1)
- acetone (1)
- albuminuria (1)
- alkaline phosphatase (1)
- beta-ketothiolase (1)
- biochemistry (1)
- biomarker (1)
- branched-chain amino acids (1)
- cPMP (1)
- chemical pathology (1)
- clinical trials (1)
- diagnosis and management (1)
- electroretinography (1)
- endocytosis (1)
- enzyme activity (1)
- epithelial transport (1)
- fatty acid metabolism (1)
- glycerol (1)
- growth hormone (1)
- guidelines (1)
- heterozygous ALPL mutation (1)
- hyperammonemia (1)
- hypoglycemia (1)
- hypophosphatasia (1)
- inherited metabolic disease (1)
- inorganic pyrophosphate (1)
- isoleucine metabolism (1)
- ketogenesis defects (1)
- ketogenez defektleri (1)
- ketoliz defektleri (1)
- ketolysis defects (1)
- keton bodies (1)
- ketone body synthesis (1)
- leucine degradation (1)
- mTOR (1)
- metabolic effects (1)
- methylmalonic acidaemia (1)
- methylmalonic acidemia (1)
- microdialysis (1)
- organic acid analysis (1)
- paediatric clinical genetics & dysmorphology (1)
- paediatric endocrinology (1)
- paediatric intensive & critical care (1)
- pathophysiology (1)
- pharmacokinetics (1)
- phenylketonuria (1)
- phosphoethanolamine (1)
- porphyria (1)
- propionic acidaemia (1)
- propionic acidemia (1)
- proteomics (1)
- proximal tubule (1)
- pyridoxal phosphate (1)
- recurrent ketoacidotic episodes (1)
- retinal degeneration (1)
- screening (1)
- surrogate endpoint (1)
- tRNA processing (1)
- tiglyglycine (1)
- valine catabolic pathway (1)
- valine degradation (1)
- γ-glutamyl cycle (1)
Disorders of the degradation of branched chain amino acids: what is new in clinics and laboratories?
(2012)
Gene expression and cell growth rely on the intracellular concentration of amino acids, which in metazoans depends on extracellular amino acid availability and transmembrane transport. To investigate the impact of extracellular amino acid concentrations on the expression of a concentrative amino acid transporter, we overexpressed the main kidney proximal tubule luminal neutral amino acid transporter B0AT1-collectrin (SLC6A19-TMEM27) in MDCK cell epithelia. Exogenously expressed proteins co-localized at the luminal membrane and mediated neutral amino acid uptake. However, the transgenes were lost over few cell culture passages. In contrast, the expression of a control transgene remained stable. To test whether this loss was due to inappropriately high amino acid uptake, freshly transduced MDCK cell lines were cultivated either with physiological amounts of amino acids or with the high concentration found in standard cell culture media. Expression of exogenous transporters was unaffected by physiological amino acid concentration in the media. Interestingly, mycoplasma infection resulted in a significant increase in transgene expression and correlated with the rapid metabolism of L-arginine. However, L-arginine metabolites were shown to play no role in transgene expression. In contrast, activation of the GCN2 pathway revealed by an increase in eIF2α phosphorylation may trigger transgene derepression. Taken together, high extracellular amino acid concentration provided by cell culture media appears to inhibit the constitutive expression of concentrative amino acid transporters whereas L-arginine depletion by mycoplasma induces the expression of transgenes possibly via stimulation of the GCN2 pathway.
3-Hydroxy-3-methylglutaryl-coenzyme A lyase (HMGCL, HMGCL) deficiency is a rare inborn error of ketogenesis. Even if the ketogenic enzyme is fully disrupted, an elevated signal for the ketone body acetoacetic acid is a frequent observation in the analysis of urinary organic acids, at least if derivatization is performed by methylation. We provide an explanation for this phenomenon and trace it back to degradation of the derivatized 3-hydroxy-3-methylglutaric acid and high temperature of the injector of the gas chromatograph.
Amino acids perform multiple essential physiological roles in humans, and accordingly, their importance to health has been the subject of extensive attention. In this special issue of the Journal of Nutrition and Metabolism, we focus on the various inborn errors of amino acid metabolism, their diagnostic challenges, new treatment approaches, and recent advances in patient monitoring as well as clinical outcomes.
Major progress occurred in understanding inborn errors of ketone body transport and metabolism between the International Congresses on Inborn Errors of Metabolism in Barcelona (2013) and Rio de Janeiro (2017). These conditions impair either ketogenesis (presenting as episodes of hypoketotic hypoglycemia) or ketolysis (presenting as ketoacidotic episodes); for both groups, immediate intravenous glucose administration is the most critical and (mHGGCS, HMGCS2) effective treatment measure.
3-Hydroxyisobutyrate Dehydrogenase (HIBADH) deficiency - a novel disorder of valine metabolism
(2021)
3-Hydroxyisobutyric acid (3HiB) is an intermediate in the degradation of the branched-chain amino acid valine. Disorders in valine degradation can lead to 3HiB accumulation and its excretion in the urine. This article describes the first two patients with a new metabolic disorder, 3-hydroxyisobutyrate dehydrogenase (HIBADH) deficiency, its phenotype and its treatment with a low-valine diet. The detected mutation in the HIBADH gene leads to nonsense-mediated mRNA decay of the mutant allele and to a complete loss-of-function of the enzyme. Under strict adherence to a low-valine diet a rapid decrease of 3HiB excretion in the urine was observed. Due to limited patient numbers and intrafamilial differences in phenotype with one affected and one unaffected individual, the clinical phenotype of HIBADH deficiency needs further evaluation.
Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle defect. The clinical presentation in female manifesting carriers varies both in onset and severity. We report on a female with insulin dependent diabetes mellitus and recurrent episodes of hyperammonemia. Since OTC activity measured in a liver biopsy sample was within normal limits, OTC deficiency was initially excluded from the differential diagnoses of hyperammonemia. Due to moderately elevated homocitrulline excretion, hyperornithinemia-hyperammonemia-homocitrullinuria-syndrome was suggested, but further assays in fibroblasts showed normal ornithine utilization. Later, when mutation analysis of the OTC gene became available, a known pathogenic missense mutation (c.533C>T) in exon 5 leading to an exchange of threonine-178 by methionine (p.Thr178Met) was detected. Skewed X-inactivation was demonstrated in leukocyte DNA. In the further clinical course the girl developed marked obesity. By initiating physical activities twice a week, therapeutic control of both diabetes and OTC deficiency improved, but obesity persisted. In conclusion, our case confirms that normal hepatic OTC enzyme activity measured in a single liver biopsy sample does not exclude a clinical relevant mosaic of OTC deficiency because of skewed X-inactivation. Mutation analysis of the OTC gene in whole blood may be a simple way to establish the diagnosis of OTC deficiency. The joint occurrence of OTC deficiency and diabetes in a patient has not been reported before.
Background: 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (HMGCLD) is an autosomal recessive disorder of ketogenesis and leucine degradation due to mutations in HMGCL.
Method: We performed a systematic literature search to identify all published cases. Two hundred eleven patients of whom relevant clinical data were available were included in this analysis. Clinical course, biochemical findings and mutation data are highlighted and discussed. An overview on all published HMGCL variants is provided.
Results: More than 95% of patients presented with acute metabolic decompensation. Most patients manifested within the first year of life, 42.4% already neonatally. Very few individuals remained asymptomatic. The neurologic long-term outcome was favorable with 62.6% of patients showing normal development.
Conclusion: This comprehensive data analysis provides a systematic overview on all published cases with HMGCLD including a list of all known HMGCL mutations.
Background 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (HMGCLD) is an autosomal recessive disorder of ketogenesis and leucine degradation due to mutations in HMGCL .
Method We performed a systematic literature search to identify all published cases. 211 patients of whom relevant clinical data were available were included in this analysis. Clinical course, biochemical findings and mutation data are highlighted and discussed. An overview on all published HMGCL variants is provided.
Results More than 95% of patients presented with acute metabolic decompensation. Most patients manifested within the first year of life, 42.4% already neonatally. Very few individuals remained asymptomatic. The neurologic long-term outcome was favorable with 62.6% of patients showing normal development.
Conclusion This comprehensive data analysis provides a systematic overview on all published cases with HMGCLD including a list of all known HMGCL mutations.